As we close 2025, Xihong Biopharma would like to share a brief year-end reflection with our valued partners.
In the first year of our global promotion journey, we took our first step at AMWC Monaco and across Southeast Asia, connecting closely with all of you in these key international markets. Our products have received inquiries from customers across more than 30 countries and regions, serving a wide range of dermatological applications. We are truly pleased to see our customers sharing their positive experiences and valuable feedback with us.
In parallel, we achieved an important milestone with the approval of two Class III medical device products, while actively advancing CE registration preparations to further strengthen the foundation of our global market expansion strategy.
At the product level, our focus remains on science-driven injectable biomaterials, including:
——PLLA-based solutions for collagen stimulation and long-term tissue regeneration
——CaHA formulations designed for structural support and biostimulation
These platforms continue to support our OEM/ODM partners with regulatory-ready, clinically oriented solutions for global markets.
Looking ahead to 2026, we are preparing to further expand our presence through Dubai Derma, IMCAS Brazil, and Beauty Istanbul in the first half of the year — and we look forward to meeting you again soon.
We sincerely thank you for your continued trust and partnership, and wish you a successful and prosperous 2026.
Xihong Biopharma
Restore Your Natural Grace
